Editas Medicine Inc (EDIT)
NASDAQ:EDIT
Holding EDIT?
Track your performance easily

Editas Medicine (EDIT) Income Statement

3,248 Followers

Editas Medicine Income Statement

Last quarter (Q2 2024), Editas Medicine's total revenue was $513.00K, a decrease of -82.23% from the same quarter last year. In Q2, Editas Medicine's net income was $-67.61M. See Editas Medicine’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 67.03M$ 78.12M$ 19.71M$ 25.54M$ 90.73M$ 20.53M
Cost of Revenue
------
Gross Profit
$ 67.03M$ 78.12M$ 19.71M$ 25.54M--
Operating Expense
$ 280.05M$ 247.30M$ 245.66M$ -218.69M$ 225.57M$ 161.45M
Operating Income
$ -213.02M$ -169.18M$ -225.95M$ -193.15M$ -134.84M$ -140.92M
Net Non Operating Interest Income Expense
-$ -17.57M-$ 2.34M$ 2.60M$ 7.31M
Other Income Expense
$ -14.49M$ -1.60M$ -1.29M$ 1.70M$ 16.26M$ -137.00K
Pretax Income
$ -193.45M$ -153.22M$ -220.43M$ -192.50M$ -115.98M$ -133.75M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -193.45M$ -153.22M$ -220.43M$ -385.00M$ -115.98M$ -133.75M
Basic EPS
$ -2.36$ -2.02$ -3.21$ -2.85$ -1.98$ -2.68
Diluted EPS
$ -2.36$ -2.02$ -3.21$ -2.85$ -1.98$ -2.68
Basic Average Shares
$ 327.81M$ 75.97M$ 68.66M$ 67.62M$ 58.61M$ 49.98M
Diluted Average Shares
$ 327.81M$ 75.97M$ 68.66M$ 67.62M$ 58.61M$ 49.98M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 280.05M$ 247.30M$ 245.66M$ -218.69M$ 225.57M$ 161.45M
Net Income From Continuing And Discontinued Operation
$ -193.45M$ -153.22M$ -220.43M$ -192.50M$ -115.98M$ -133.75M
Normalized Income
$ -102.50M-$ -174.14M-$ -115.98M$ -133.75M
Interest Expense
-----$ -7.31M
EBIT
$ -203.58M$ -169.18M$ -220.43M$ -192.50M$ -134.84M$ -140.92M
EBITDA
$ -198.77M$ -163.12M$ -214.13M$ -187.40M$ -130.88M$ -138.09M
Currency in USD

Editas Medicine Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis